title: Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin.
abstract: Ataxic sensory neuronopathy with Sjögren's syndrome is a devastating neurologic complication for which there is no established treatment. IV immunoglobulin (IVIG) was given to five patients with severe disabilities for an average of 12 years. Four patients showed remarkable improvement, two of whom responded after the first course. The authors conclude that IVIG is safe and effective to treat even chronically debilitated patients who have the disease, presumably because it ameliorates smoldering inflammation.
authors.affiliation: Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan. takahashiy-int@h.u-tokyo.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Takata
authors.forename: M
authors.initials: M
authors.lastname: Hoshino
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: I
authors.initials: I
authors.lastname: Kanazawa
mesh_terms: D000368:Aged; D001259:Ataxia / Q000150:complications / Q000188:drug therapy*; D002908:Chronic Disease; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects; D009460:Neurologic Examination; D010865:Pilot Projects; D011115:Polyneuropathies / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012720:Severity of Illness Index; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy*; D013116:Spinal Cord / Q000473:pathology; D013497:Sural Nerve / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous